A Phase 2 interventional study of r-hLH + r-hFSH and r-hFSH in Infertility and Ovulation Induction, sponsored by Merck KGaA, Darmstadt, Germany. Terminated at 1 site in Spain. Open to female participants aged 35 Years to 42 Years. Per ClinicalTrials.gov, last updated 2014-02-27.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing lutropin alfa in Infertility — 1 open to participants now, 1 under way, 1 of them phase 3. lutropin alfa · Infertility.
Among the 11 studies testing lutropin alfa in Infertility, this one is the 5th largest by enrollment, is one of 2 that started in 2007, is one of 3 in phase 2, and was the 4th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 11 studies testing lutropin alfa in Infertility is open now, in 1 country. Recruiting first, the newest first:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Sites in Japan
Ages 18–42 · Women only
By country, each count listing its studies:
lutropin alfa: first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 35 Years to 42 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2007.
This study's enrollment of 93 is below the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 90 across the 11 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 7 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
44 studies in Infertility by Merck KGaA, Darmstadt, Germany: 1 open now, 1 under way, 1 of them phase 3. Of 43 finished, 21 (49%) have results posted.
Among the 44 studies in Infertility by Merck KGaA, Darmstadt, Germany, this one is the 18th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2007, is one of 6 in phase 2, and was the 14th registered.
Merck KGaA, Darmstadt, Germany’s Infertility studies by the year they started, since 1999.
1 of the studies testing lutropin alfa in Infertility that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340827Phase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyA Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing lutropin alfa in Infertility, from their registry updates:
Among Merck KGaA, Darmstadt, Germany’s 44 in Infertility:
This tab as a report to print or save as PDF → With an account.
Ovarian reserve is related to chronological age; 35 years of age is the accepted threshold for significant decline in assisted reproductive technologies (ART) success with scarce follicular recruitment and poor oocyte retrieval. New therapeutic schemes are sought to improve follicular response in ovarian ageing because of the increasing number of infertile women aged older than 35 years who are trying to get pregnant. The advent of gonadotropin releasing hormone analogue antagonist (GnRHant) offers new perspectives to address the issues related to advanced reproductive age since it prevents premature luteinizing hormone (LH) surges while not causing suppression in the early follicular phase. Gonadotropin releasing hormone analogue antagonists are administered in the latter stage of the ovarian stimulation to prevent LH surge by competitive blockade of gonadotropin releasing hormone (GnRH) receptors, thus producing a marked decrease in LH levels just when the interplay between follicle stimulating hormone (FSH) and LH becomes important to complete follicular development and oocyte competence. Some studies in the past have shown the potential of recombinant human LH (r-hLH) supplementation in women of advanced reproductive age to improve oocyte quality, but these studies are of small size and did not provide data on the physiological mechanism behind the benefit obtained.
This randomized, comparative, parallel controlled Phase II study will be conducted in infertile female subjects aged 35-42 years undergoing in-vitro fertilization (IVF)/intra cytoplasmic sperm injection (ICSI), to investigate whether the addition of r-hLH (when the lead follicle is greater than [>] 14 millimeter [mm] in size), to the standard protocol with recombinant human FSH (r-hFSH) under GnRHant, improves the number and quality of oocytes retrieved, implantation rate, and pregnancy rate, while assessing the hormonal milieu in the ovarian follicular fluid. Comparison will be performed against ovarian stimulation without addition of r-hLH, that is (i.e.) with r-hFSH under GnRHant alone.
Preclinical pharmacology studies have demonstrated that r-hLH has a LH/human chorionic gonadotropin (hCG) receptor affinity similar to pituitary human luteinizing hormone (p-hLH), and is biologically active in-vitro in stimulating steroidogenesis and in promoting oocyte germinal vesicle breakdown. Several clinical studies have investigated the usefulness of r-hLH supplementation in normal ovulatory women undergoing ART and in almost all of them sub-populations of subjects have been identified who will benefit, when r-hLH is added to FSH.
OBJECTIVES
Primary objectives:
Secondary objectives:
Tertiary objectives:
All subjects will undergo treatment with r-hFSH at a daily dose of 300-450 IU by subcutaneous route starting on the stimulation Day 1 (S1) until r-hCG administration. Upon detection of a lead follicle > 14 mm in diameter, GnRHant 0.25 milligram (mg)/day subcutaneous administration will be initiated and continued up to r-hCG administration day. Subjects will be then randomly allocated (at any time between S1 and GnRHant initiation day) either to additional treatment with r-hLH at a daily fixed dose of 150 IU or continue treatment with r-hFSH alone. Gonadotropin releasing hormone antagonist and combined treatment with r-hLH plus (+) r-hFSH or r-hFSH alone will be administered until at least one follicle > 18 mm in diameter and two additional follicles > 16 mm in diameter are present and E2 levels are commensurate with the number and size of follicles present. A single injection of 250-500 microgram of r-hCG, will be given to induce final follicular maturation within 36 hours of the last r-hLH and/or r-hFSH injections and on the same day of the last GnRHant morning administration. Oocytes will be retrieved 34-38 hours after r-hCG administration, assessed, and fertilized in-vitro by ICSI. Not more than 3 embryos will be replaced on day 2 or 3 after OPU. The luteal phase will be supported by a daily vaginal administration of natural progesterone, starting after OPU and continuing either up to menstruation or the pregnancy test or, if the subject is pregnant, for at least 30 days after laboratory evidence of pregnancy. Each subject will be followed-up and the treatment outcome (pregnancy or menstruation) will be recorded.
For all subjects who received r-hCG and do not menstruate, a blood sample will be collected for local determination of serum beta-hCG level between post-hCG days 15-20. If positive (beta-hCG > 10 International Unit/liter [IU/L]), it should be confirmed by performing a second test within one week later. An ultrasound scan (US) will be performed at post-hCG days 35-42 on all subjects who will become pregnant provided that no miscarriage has occurred. The number of fetal sacs and fetal heart activity will be recorded. Active follow-up of all pregnancies will be performed, including those subjects withdrawn from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: r-hLH + r-hFSH · Drug: Recombinant Human Choriogonadotropin (r-hCG) · Drug: GnRH antagonist
Drug: r-hFSH · Drug: Recombinant Human Choriogonadotropin (r-hCG) · Drug: GnRH antagonist
Drug page: Lutropin alfa
Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
Also known as: Luveris®, Lutropin alfa
Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.
The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
Also known as: Ovitrelle®
The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (\>=) 14 mm, and maintained until at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
Also known as: Cetrotide®
Number of Oocytes Retrieved
Number of oocytes retrieved per reporting group on the day of ovum pick-up (OPU) (34-38 hours post r-hCG day) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization (IVF) in order to remove oocytes from the ovary of the female participant, enabling fertilization outside the body.
Time frame: Ovum pick-up (OPU) day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
Number of Mature Oocytes Retrieved
Number of mature oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. The nuclear maturity is assessed based on the presence of a germinal vesicle (GV) or whether oocytes were in metaphase I (Meta-I) or II (Meta-II) stage or atretic.
Time frame: OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)
Ovarian Hyper Stimulation Syndrome (OHSS) is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.
Time frame: S1 to 1 month ± 1 week post r-hCG day (end of stimulation cycle [approximately 9 days])
Number of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS)
Ovarian Hyper Stimulation Syndrome (OHSS) is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.
Time frame: S1 to 1 month ± 1 week post r-hCG day (end of stimulation cycle [approximately 9 days])
Number of Participants With Adverse Events (AEs)
An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.
Time frame: S1 to 1 month ± 1 week post r-hCG day (end of stimulation cycle [approximately 9 days])
Number of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day
Time frame: r-hCG day (end of stimulation cycle [approximately 9 days])
Endometrial Thickness on Recombinant Human Choriogonadotropin (r-hCG) Day
Endometrial thickness measurement was performed on the day of r-hCG administration.
Time frame: r-hCG day (end of stimulation cycle [approximately 9 days])
Number of Fertilized Oocytes (2 Pronuclei [PN])
Oocytes were fertilized using Intra-cytoplasmic Sperm Injection (ICSI) technique which is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. The appearance of 2PN is the first sign of successful fertilization as observed during in vitro fertilization, and is usually observed after ICSI. The zygote is then termed 2PN.
Time frame: OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
Number of Fertilized Oocytes at Stage 2 Pronuclei (2PN) or Higher Than 2PN
Oocytes were fertilized using ICSI technique which is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. The appearance of 2PN is the first sign of successful fertilization as observed during in vitro fertilization, and is usually observed after ICSI. The zygote is then termed 2PN. Fertilized oocytes at stage higher then 2PN are those oocytes which consist more than 2 pronuclei like oocyte having 3 pronuclei termed as 3PN, oocyte having 4 pronuclei termed as 4PN.
Time frame: Day 35-42 post r-hCG day (end of stimulation cycle [approximately 9 days])
Number and Quality of Embryos
Embryos were classified into 5 different grades (1 to 5) based on their capacity of implantation. Grade 1 embryos were those with best capacity of implantation and Grade 5 embryos were those with worst capacity of implantation.
Time frame: Day 2-3 post OPU (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
Implantation Rate
Implantation rate was measured as the number of gestational sacs observed, divided by the number of embryos transferred multiplied by 100.
Time frame: Day 35-42 post OPU (34-38 hours post r-hCG day {end of stimulation cycle [approximately 9 days]})
Number of Participants With Clinical Pregnancies
Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.
Time frame: Day 35-42 post r-hCG day (end of stimulation cycle [approximately 9 days])
Number of Participants in Whom Recombinant Human Chorionic Gonadotropin (r-hCG) Was Not Administered Due to Poor Response
Poor response was defined as 3 or less follicles of greater than or equal to 12 mm developing following at least 7 days of study treatment.
Time frame: r-hCG day (end of stimulation cycle [approximately 9 days])
Number of Ovarian Stimulation Days
Ovarian stimulation included from first r-hFSH injection (S1) until day on which r-hCG was administered (r-hCG day).
Time frame: Day 1 of stimulation period (S1) up to r-hCG day (end of stimulation cycle [approximately 9 days])
Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH)
Time frame: Day 1 of stimulation period (S1) up to r-hCG day (end of stimulation cycle [approximately 9 days])
Estradiol (E2) Levels on r-hCG Day
Time frame: r-hCG day (end of stimulation cycle [approximately 9 days])
Follicular Levels of Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and Human Chorionic Gonadotropin (hCG) at Ovum Pick up (OPU)
Time frame: OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
Follicular Levels of Estradiol (E2) at Ovum Pick up (OPU)
Time frame: OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
Follicular Levels of Testosterone (T) at Ovum Pick up (OPU)
Time frame: OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
| Milestone | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Started | 46 | 47 |
| Completed | 31 | 34 |
| Not completed | 15 | 13 |
| Withdrew: Withdrawal before r-hcg administration | 2 | 3 |
| Withdrew: Withdrawal between rhcg-ovum pickup(opu) | 4 | 8 |
| Withdrew: Withdrawal between opu - embryo transfer | 8 | 2 |
| Withdrew: Randomized but not treated | 1 | 0 |
Number of oocytes retrieved per reporting group on the day of ovum pick-up (OPU) (34-38 hours post r-hCG day) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization (IVF) in order to remove oocytes from the ovary of the female participant, enabling fertilization outside the body.
| oocytes | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Number of Oocytes Retrieved | 10 ± 3.8 | 10 ± 5.2 |
Number of mature oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. The nuclear maturity is assessed based on the presence of a germinal vesicle (GV) or whether oocytes were in metaphase I (Meta-I) or II (Meta-II) stage or atretic.
| mature oocytes | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Geminal vesicle (GV) | 60 | 37 |
| Meta-I | 44 | 26 |
| Meta-II | 275 | 292 |
| Atresic | 10 | 4 |
Ovarian Hyper Stimulation Syndrome (OHSS) is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.
| participants | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS) | 0 | 0 |
Ovarian Hyper Stimulation Syndrome (OHSS) is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.
| cycles | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Number of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS) | 0 | 0 |
An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.
| participants | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 3 | 0 |
| follicles | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Number of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day | 8.6 ± 3.9 | 7.4 ± 3.9 |
Endometrial thickness measurement was performed on the day of r-hCG administration.
| mm | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Endometrial Thickness on Recombinant Human Choriogonadotropin (r-hCG) Day | 9.5 ± 2.1 | 8.8 ± 2.2 |
Oocytes were fertilized using Intra-cytoplasmic Sperm Injection (ICSI) technique which is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. The appearance of 2PN is the first sign of successful fertilization as observed during in vitro fertilization, and is usually observed after ICSI. The zygote is then termed 2PN.
| 2PN oocytes | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Number of Fertilized Oocytes (2 Pronuclei [PN]) | 203 | 203 |
Oocytes were fertilized using ICSI technique which is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. The appearance of 2PN is the first sign of successful fertilization as observed during in vitro fertilization, and is usually observed after ICSI. The zygote is then termed 2PN. Fertilized oocytes at stage higher then 2PN are those oocytes which consist more than 2 pronuclei like oocyte having 3 pronuclei termed as 3PN, oocyte having 4 pronuclei termed as 4PN.
| oocytes | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Number of Fertilized Oocytes at Stage 2 Pronuclei (2PN) or Higher Than 2PN | 210 | 210 |
Embryos were classified into 5 different grades (1 to 5) based on their capacity of implantation. Grade 1 embryos were those with best capacity of implantation and Grade 5 embryos were those with worst capacity of implantation.
| embryos | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| 1 | 22 | 39 |
| 2 | 46 | 35 |
| 3 | 56 | 49 |
| 4 | 18 | 13 |
| 5 | 64 | 70 |
Implantation rate was measured as the number of gestational sacs observed, divided by the number of embryos transferred multiplied by 100.
| percent sacs per embryo | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Implantation Rate | 30 ± 30 | 20 ± 30 |
Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.
| participants | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Number of Participants With Clinical Pregnancies | 14 | 12 |
Poor response was defined as 3 or less follicles of greater than or equal to 12 mm developing following at least 7 days of study treatment.
| participants | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Number of Participants in Whom Recombinant Human Chorionic Gonadotropin (r-hCG) Was Not Administered Due to Poor Response | 1 | 3 |
Ovarian stimulation included from first r-hFSH injection (S1) until day on which r-hCG was administered (r-hCG day).
| days | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Number of Ovarian Stimulation Days | 9.4 ± 1.3 | 8.8 ± 1.5 |
| IU | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH) | 2916.1 ± 555.9 | 2861.7 ± 693.8 |
| picogram/milliter (pg/mL) | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Estradiol (E2) Levels on r-hCG Day | 1813.9 ± 1063.6 | 1362.9 ± 774.1 |
| milli international unit (mIU)/mL | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| LH levels at OPU | 1.8 ± 0.9 | 2.0 ± 0.9 |
| FSH levels at OPU | 8.3 ± 3.0 | 9.0 ± 3.7 |
| hCG levels at OPU | 142.2 ± 72.7 | 136.2 ± 65.8 |
| pg/mL | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Follicular Levels of Estradiol (E2) at Ovum Pick up (OPU) | 454508.0 ± 189835.8 | 349605.3 ± 203895.8 |
| nanogram/milliliter (ng/mL) | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Follicular Levels of Testosterone (T) at Ovum Pick up (OPU) | 5.9 ± 1.5 | 6.0 ± 1.8 |
Collected over S1 up to 1 month ± 1 week post r-hCG day (end of stimulation cycle [approximately 9 days]). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| r-hFSH + r-hLH | — | 2/45 (4.4%) | 1/45 (2.2%) |
| r-hFSH | — | 0/47 (0%) | 0/47 (0%) |
| Event | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 2/45 | 0/47 |
| Event | r-hFSH + r-hLH | r-hFSH |
|---|---|---|
| VomitingGastrointestinal disorders | 1/45 | 0/47 |
| Age, Continuous(years) | r-hFSH + r-hLH | r-hFSH | Total |
|---|---|---|---|
| Mean | 36.6 ± 2.6 | 36.3 ± 3.0 | 36.4 ± 2.8 |
| Sex: Female, Male(Participants) | r-hFSH + r-hLH | r-hFSH | Total |
|---|---|---|---|
| Female | 45 | 47 | 92 |
| Male | 0 | 0 | 0 |
The record gives a start of Nov 2007, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lutropin alfa
Merck KGaA, Darmstadt, Germany →